<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Tauroursodeoxycholic acid (TUDCA), a hydrophilic <z:chebi fb="0" ids="3098">bile acid</z:chebi>, is a strong modulator of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in both hepatic and nonhepatic cells, and appears to function by inhibiting <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> membrane perturbation </plain></SENT>
<SENT sid="1" pm="."><plain>Excitotoxicity, metabolic compromise, and <z:mp ids='MP_0003674'>oxidative stress</z:mp> are major determinants of cell <z:hpo ids='HP_0011420'>death</z:hpo> after <z:e sem="disease" ids="C0007786" disease_type="Disease or Syndrome" abbrv="">brain ischemia</z:e>-reperfusion injury </plain></SENT>
<SENT sid="2" pm="."><plain>However, some neurons undergo delayed cell <z:hpo ids='HP_0011420'>death</z:hpo> that is characteristic of <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>Therefore, the authors examined whether TUDCA could reduce the injury associated with <z:hpo ids='HP_0011009'>acute</z:hpo> <z:hpo ids='HP_0001297'>stroke</z:hpo> in a well-characterized model of transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Their model of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> resulted in marked cell <z:hpo ids='HP_0011420'>death</z:hpo> with prominent terminal deoxynucleotidyl transferase-mediated 2;-deoxyuridine 5;-<z:chebi fb="0" ids="15266,18036">triphosphate</z:chebi>-<z:chebi fb="1" ids="15956">biotin</z:chebi> nick end labeling (TUNEL) within the ischemic penumbra, <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> swelling, and caspase activation </plain></SENT>
<SENT sid="5" pm="."><plain>Tauroursodeoxycholic acid administered 1 hour after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> resulted in significantly <z:mp ids='MP_0004789'>increased bile acid levels</z:mp> in the brain, improved neurologic function, and an approximately 50% reduction in <z:mpath ids='MPATH_124'>infarct</z:mpath> size 2 and 7 days after reperfusion </plain></SENT>
<SENT sid="6" pm="."><plain>In addition, TUDCA significantly reduced the number of TUNEL-positive brain cells, <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> swelling, and partially inhibited caspase-3 processing and substrate cleavage </plain></SENT>
<SENT sid="7" pm="."><plain>These findings suggest that the mechanism for in vivo neuroprotection by TUDCA is, in part, mediated by inhibition of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> perturbation and subsequent caspase activation leading to apoptotic cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>Thus, TUDCA, a clinically safe molecule, may be useful in the treatment of <z:hpo ids='HP_0001297'>stroke</z:hpo> and possibly other <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-associated <z:hpo ids='HP_0011009'>acute</z:hpo> and <z:hpo ids='HP_0011010'>chronic</z:hpo> injuries to the brain </plain></SENT>
</text></document>